Developer docs
API playgroundTry for free, no card

Search company profiles

Ribon Therapeutics

Full company profile

uuid0000kpk

Namestring
Ribon Therapeutics
Legal namestring
Ribon Therapeutics, Inc.
Websiteurl
ribontx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicine therapeutics that target stress-related biological pathways in cancer and inflammation. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company's scientific premise is that modulating cellular stress support pathways represents a differentiated mechanism for treating oncology and immunology indications. Its lead clinical program is RBN-2397, a PARP7 inhibitor for cancer, and its second clinical-stage program, RBN-3143, is being developed for immunology applications. Both candidates are positioned as precision interventions in stress-pathway biology and constitute the entirety of Ribon's disclosed clinical pipeline.

The company is privately held and pre-revenue, operating under a standard clinical-stage biotech model in which operations are funded by equity capital and strategic corporate investment. Cumulative disclosed funding totals approximately $259 million across rounds from 2015 through 2023, including seed and Series A rounds in 2015–2016, a $20 million round in 2017, a $65 million Series B in January 2019 led by Novartis Venture Fund, a $65 million Series C in June 2021 co-led by Deerfield Management and U.S. Venture Partners, a $50 million financing from K2 HealthVentures in April 2022, an SEC-registered $25 million offering in December 2022, and a $25 million strategic investment from Pfizer announced in January 2023. Investor participation spans leading healthcare venture firms (Deerfield, U.S. Venture Partners, The Column Group, Euclidean Capital, Osage University Partners) and corporate venture arms of major pharma (AbbVie, Bristol-Myers Squibb, Johnson & Johnson Innovation, Novartis Venture Fund, Takeda Ventures, Pfizer, Google Ventures).

Ribon retains full control over its pipeline and relies on strategic pharma collaborations rather than direct product distribution. The Pfizer collaboration exemplifies this model: capital and advisory support flow to Ribon in exchange for development collaboration on RBN-2397 and RBN-3143, with Ribon maintaining pipeline autonomy. Headcount of 11–50 employees reflects the company's focused clinical-stage scale, and pricing details are not publicly disclosed because no therapeutic candidates have reached commercialization. The intended exit pathways consistent with this model are out-licensing, co-development partnerships, or acquisition by a larger pharmaceutical company.

Short descriptiontext

Clinical-stage biotechnology company developing precision therapeutics that target stress-related biological pathways in cancer and inflammation, with lead candidates RBN-2397 (PARP7 inhibitor) and RBN-3143 (immunology program).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
PARP7 inhibitors, precision oncology therapeutics, clinical-stage biotechnology, cancer drug development, mono-parp inhibitors
Industry1 code
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage Oncology Therapeutics
Social media profiles2 records
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicines that target stress response pathways in cancer and inflammatory diseases. Its lead clinical candidates are RBN-2397, a first-in-class PARP7 inhibitor, and RBN-3143, advancing novel monoPARP-targeted therapies toward patients with cancer and inflammatory conditions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ribon Therapeutics is a biotechnology company developing a precision medicine pipeline targeting stress-related biological pathways in cancer and inflammation. The company's clinical programs include RBN-2397, a PARP7 inhibitor for cancer treatment, and RBN-3143, an immunology program, both targeting stress support pathways.

Product and service2 records
1RBN-2397
CategoryPrecision Oncology Therapeutics
Description

RBN-2397 is a first-in-class small molecule inhibitor of PARP7, designed to restore Type I interferon signaling in tumors. It is being developed for patients with cancer as a precision oncology therapeutic candidate.

2RBN-3143
CategoryPrecision Oncology Therapeutics
Description

RBN-3143 is a clinical-stage candidate targeting monoPARP biology, developed for cancer and inflammatory diseases as part of Ribon's precision medicine pipeline.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic-lethality and DNA-damage-response therapies. Directly comparable to Ribon as a similarly sized clinical-stage biotech pursuing novel mechanism oncology drugs with pharma partnership optionality.

TypeDirect peer
Description

Precision oncology company developing synthetic-lethality-based therapies including a clinical-stage PARG inhibitor. Closely comparable to Ribon in stage, modality (small molecules), oncology focus, and approach of targeting stress/DNA-damage-response pathways.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small-molecule kinase inhibitors against allosteric and mutant targets. Comparable in size, stage, and therapeutic approach to Ribon's clinical-stage precision oncology focus.

TypeDirect peer
Description

Clinical-stage precision oncology biotech targeting chromatin regulatory biology. Comparable to Ribon in stage, modality, and oncology focus with a similarly novel mechanism approach and pharma-backed financing history.

5Nuvalent
TypeDirect peer
Description

Clinical-stage precision oncology company developing kinase inhibitors with a focus on overcoming resistance mutations. Comparable in clinical-stage status, small-molecule modality, and pursuit of differentiated precision oncology targets.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small-molecule inhibitors of the RAS/MAPK pathway. Comparable as a similarly positioned clinical-stage precision oncology biotech with multi-program pipeline.

TypeDirect peer
Description

Clinical-stage biotech developing targeted protein degraders in oncology and immunology. Comparable in stage, indication overlap (oncology and immunology), and small-molecule-based precision medicine approach.

TypeEmerging player
Description

Tech-enabled drug discovery company using AI/ML-driven phenotypic screening to develop precision medicines. Comparable to Ribon in clinical-stage pipeline development but applies a differentiated platform/AI-discovery approach.

TypeBroad incumbent
Description

Computational chemistry/drug discovery platform with both internal pipeline and external partnerships. Broadly comparable to Ribon in precision small-molecule drug development and oncology focus, though operating at a much larger and more diversified scale.

TypeBroad incumbent
Description

Commercial-stage precision oncology company developing small-molecule kinase inhibitors. Broader incumbent in the same clinical precision-oncology small-molecule space Ribon operates in, with approved product providing established commercial benchmarks.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ribon Therapeutics

Clinical-stage Oncology Therapeuticsribontx.com

Clinical-stage biotechnology company developing precision therapeutics that target stress-related biological pathways in cancer and inflammation, with lead candidates RBN-2397 (PARP7 inhibitor) and RBN-3143 (immunology program).

What Ribon Therapeutics does

Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicine therapeutics that target stress-related biological pathways in cancer and inflammation. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company's scientific premise is that modulating cellular stress support pathways represents a differentiated mechanism for treating oncology and immunology indications. Its lead clinical program is RBN-2397, a PARP7 inhibitor for cancer, and its second clinical-stage program, RBN-3143, is being developed for immunology applications. Both candidates are positioned as precision interventions in stress-pathway biology and constitute the entirety of Ribon's disclosed clinical pipeline.

The company is privately held and pre-revenue, operating under a standard clinical-stage biotech model in which operations are funded by equity capital and strategic corporate investment. Cumulative disclosed funding totals approximately $259 million across rounds from 2015 through 2023, including seed and Series A rounds in 2015–2016, a $20 million round in 2017, a $65 million Series B in January 2019 led by Novartis Venture Fund, a $65 million Series C in June 2021 co-led by Deerfield Management and U.S. Venture Partners, a $50 million financing from K2 HealthVentures in April 2022, an SEC-registered $25 million offering in December 2022, and a $25 million strategic investment from Pfizer announced in January 2023. Investor participation spans leading healthcare venture firms (Deerfield, U.S. Venture Partners, The Column Group, Euclidean Capital, Osage University Partners) and corporate venture arms of major pharma (AbbVie, Bristol-Myers Squibb, Johnson & Johnson Innovation, Novartis Venture Fund, Takeda Ventures, Pfizer, Google Ventures).

Ribon retains full control over its pipeline and relies on strategic pharma collaborations rather than direct product distribution. The Pfizer collaboration exemplifies this model: capital and advisory support flow to Ribon in exchange for development collaboration on RBN-2397 and RBN-3143, with Ribon maintaining pipeline autonomy. Headcount of 11–50 employees reflects the company's focused clinical-stage scale, and pricing details are not publicly disclosed because no therapeutic candidates have reached commercialization. The intended exit pathways consistent with this model are out-licensing, co-development partnerships, or acquisition by a larger pharmaceutical company.

Ribon Therapeutics firmographics

Firmographics
Name
Ribon Therapeutics
Legal name
Ribon Therapeutics, Inc.
Website
https://ribontx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Clinical-stage biotechnology company developing precision therapeutics that target stress-related biological pathways in cancer and inflammation, with lead candidates RBN-2397 (PARP7 inhibitor) and RBN-3143 (immunology program).
Ownership category
akta.pro rank

Ribon Therapeutics industry classification

Industry
Product category
Clinical-stage Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • PARP7 inhibitors
  • Precision oncology therapeutics
  • Clinical-stage biotechnology
  • Cancer drug development
  • Mono-parp inhibitors

Where Ribon Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ribon Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels2 records

Ribon Therapeutics product offering

Product offering

Core offering

Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicines that target stress response pathways in cancer and inflammatory diseases. Its lead clinical candidates are RBN-2397, a first-in-class PARP7 inhibitor, and RBN-3143, advancing novel monoPARP-targeted therapies toward patients with cancer and inflammatory conditions.

Product overview

Ribon Therapeutics is a biotechnology company developing a precision medicine pipeline targeting stress-related biological pathways in cancer and inflammation. The company's clinical programs include RBN-2397, a PARP7 inhibitor for cancer treatment, and RBN-3143, an immunology program, both targeting stress support pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • RBN-2397 RBN-2397 is a first-in-class small molecule inhibitor of PARP7, designed to restore Type I interferon signaling in tumors. It is being developed for patients with cancer as a precision oncology therapeutic candidate.
  • RBN-3143 RBN-3143 is a clinical-stage candidate targeting monoPARP biology, developed for cancer and inflammatory diseases as part of Ribon's precision medicine pipeline.

Companies that use Ribon Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Ribon Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ribon Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Ribon Therapeutics competitors and assessment

Company assessment

Direct peers

  • Tango Therapeutics: Clinical-stage precision oncology company developing synthetic-lethality and DNA-damage-response therapies. Directly comparable to Ribon as a similarly sized clinical-stage biotech pursuing novel mechanism oncology drugs with pharma partnership optionality.
  • Repare Therapeutics: Precision oncology company developing synthetic-lethality-based therapies including a clinical-stage PARG inhibitor. Closely comparable to Ribon in stage, modality (small molecules), oncology focus, and approach of targeting stress/DNA-damage-response pathways.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing small-molecule kinase inhibitors against allosteric and mutant targets. Comparable in size, stage, and therapeutic approach to Ribon's clinical-stage precision oncology focus.
  • Foghorn Therapeutics: Clinical-stage precision oncology biotech targeting chromatin regulatory biology. Comparable to Ribon in stage, modality, and oncology focus with a similarly novel mechanism approach and pharma-backed financing history.
  • Nuvalent: Clinical-stage precision oncology company developing kinase inhibitors with a focus on overcoming resistance mutations. Comparable in clinical-stage status, small-molecule modality, and pursuit of differentiated precision oncology targets.
  • Erasca: Clinical-stage precision oncology company developing small-molecule inhibitors of the RAS/MAPK pathway. Comparable as a similarly positioned clinical-stage precision oncology biotech with multi-program pipeline.
  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders in oncology and immunology. Comparable in stage, indication overlap (oncology and immunology), and small-molecule-based precision medicine approach.

Emerging players

  • Recursion Pharmaceuticals: Tech-enabled drug discovery company using AI/ML-driven phenotypic screening to develop precision medicines. Comparable to Ribon in clinical-stage pipeline development but applies a differentiated platform/AI-discovery approach.

Broad incumbents

  • Schrödinger: Computational chemistry/drug discovery platform with both internal pipeline and external partnerships. Broadly comparable to Ribon in precision small-molecule drug development and oncology focus, though operating at a much larger and more diversified scale.
  • Deciphera Pharmaceuticals: Commercial-stage precision oncology company developing small-molecule kinase inhibitors. Broader incumbent in the same clinical precision-oncology small-molecule space Ribon operates in, with approved product providing established commercial benchmarks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Ribon Therapeutics social profiles

Digital presence

Ribon Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ribon Therapeutics leadership team

Management profile

Number of profiles

Ribon Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ribon Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ribon Therapeutics

What does Ribon Therapeutics do?

Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicines that target stress response pathways in cancer and inflammatory diseases. Its lead clinical candidates are RBN-2397, a first-in-class PARP7 inhibitor, and RBN-3143, advancing novel monoPARP-targeted therapies toward patients with cancer and inflammatory conditions.

Is Ribon Therapeutics a public or private company?

Ribon Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ribon Therapeutics founded?

Ribon Therapeutics was founded in 2015. It employs 1 to 10 people.

Where is Ribon Therapeutics based?

Ribon Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are Ribon Therapeutics's main competitors?

Direct peers on record are Tango Therapeutics, Repare Therapeutics, Black Diamond Therapeutics, Foghorn Therapeutics, Nuvalent, Erasca and Kymera Therapeutics. Recursion Pharmaceuticals is listed as an emerging player. Broad incumbents are Schrödinger and Deciphera Pharmaceuticals.

Does Ribon Therapeutics have an API?

No public API is recorded for Ribon Therapeutics.

What industry is Ribon Therapeutics in?

Ribon Therapeutics's product category is Clinical-stage Oncology Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comPARP Inhibitor Clinical Pipeline Demonstrates Strong Momentum with 30+ Companies Advancing Innovative Therapies | DelveInsightDelveInsight published a market research report on the PARP inhibitor pipeline, highlighting that over 30 pharmaceutical and biotech companies are developing more than 30 therapies targeting PARP inhibition as of February 2026. Key clinical milestones include AstraZeneca initiating a Phase I/IIa study for AZD5305 on February 19, EMD Serono launching a Phase II trial for tuvusertib on February 18, and the Jonsson Comprehensive Cancer Center beginning a Phase Ib/II study on February 12. The report profiles leading companies including TESARO, AstraZeneca, BeiGene, Eisai, Sun BioPharma, IMPACT Therapeutics, and Ribon Therapeutics.UflRibonaut Therapeutics receives ‘panelists’ choice’ award at UF Innovate biotechnology pitch eventUF Innovate held its first biotechnology-focused GatorPitch event in Jupiter, Florida on March 5, 2025, showcasing five University of Florida life sciences startups to investors. Ribonaut Therapeutics, a UF company co-founded by Matthew Disney and developing RNA-targeting small molecules for neurological diseases and movement disorders, received the "Panelists' Choice" award and became the first BioPitch Launchpad Winner from BioFlorida, advancing to the statewide BioPitch competition. The BioPitch Launchpad Initiative winners will compete for $100,000 in non-dilutive prizes at the BioFlorida Innovation Conference in Orlando, October 14-16, 2026.Business Wire BlogRibon Therapeutics Announces $25 Million Equity Investment from PfizerRibon Therapeutics announced a $25 million equity investment from Pfizer to support clinical development of its oncology and immunology programs. The funds will advance RBN-2397, a PARP7 inhibitor, and RBN-3143, a PARP14 inhibitor, with Pfizer's Dr. Rickert joining the advisory board.Endpoints NewsPfiz­er in­vests in Ri­bon Ther­a­peu­tics; Ar­genx gets PDU­FA date ex­ten­sionPfizer has invested $25 million in Massachusetts-based biotech firm Ribbon Therapeutics to provide financial backing. The article also notes that Argenx received an extension for its PDUFA date.BioSpaceRibon Therapeutics Announces $25 Million Equity Investment from PfizerRibon Therapeutics has announced a $25 million equity investment from Pfizer to support the development of its clinical programs RBN-2397 and RBN-3143. This investment will aid Ribon in advancing its oncology and immunology treatments while leveraging Pfizer's expertise in global development. Ribon will retain control over its clinical development despite this partnership.SecSEC FORM DRibon Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on December 22, 2022, notifying regulators of an exempt securities offering under Rule 506(b). The filing discloses a total offering amount of $25,000,000 USD for equity securities.BioSpaceRibon Therapeutics Announces Key Management PromotionsRibon Therapeutics promoted Heike Keilhack to Chief Scientific Officer and Kevin Kuntz to Chief Drug Development Officer. Both previously held senior vice president roles, and the company highlighted progress on its RBN-2397 clinical trial and IND-enabling studies for RBN-3143.Venture Capital Access OnlineRibon Therapeutics Secures $65 Million FinancingRibon Therapeutics, a Cambridge, Massachusetts biotechnology company, closed a $65 million financing on July 14, 2021, led by Deerfield Management and U.S. Venture Partners with support from Avego BioScience Capital, GV, Monashee Investment Management and Peregrine Ventures. The company said proceeds will fund clinical development of its lead candidates RBN-2397 in cancer and RBN-3143 in inflammation, plus additional drug discovery from its BEACON+ platform.FinSMEsRibon Therapeutics Raises $65M in FundingRibon Therapeutics, a Cambridge-based clinical-stage biotechnology company, has closed a $65 million financing round. The investment was led by Deerfield Management and U.S. Venture Partners, with participation from several new and existing investors including GV, AbbVie Ventures, and Johnson & Johnson Innovation. The company intends to use the proceeds to support the clinical development of its novel precision medicine candidates.